{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T01:17:28Z","timestamp":1760577448155},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13346-020-00709-4","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T21:02:41Z","timestamp":1582059761000},"page":"1314-1326","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Fabrication, optimization, and in vitro\/in vivo evaluation of diclofenac epolamine flash tablet"],"prefix":"10.1007","volume":"10","author":[{"given":"Mohamed Ahmed","family":"El-Nabarawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Hassen","family":"Elshafeey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina Mohamed","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amani M.","family":"El Sisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,18]]},"reference":[{"issue":"1","key":"709_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1208\/s12249-016-0525-z","volume":"18","author":"M Montenegro-Nicolini","year":"2017","unstructured":"Montenegro-Nicolini M, Morales JO. Overview and future potential of buccal mucoadhesive films as drug delivery systems for biologics. AAPS PharmSciTech. 2017;18(1):3\u201314.","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"709_CR2","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1208\/s12249-017-0777-2","volume":"18","author":"L Chen","year":"2017","unstructured":"Chen L, Daoxiao CH, Xinhui ZH, Hong S, Yindi K, Rongyue ZH. Orally fast-dissolving films containing lutein nanocrystals for improved bioavailability: formulation development, in vitro and in vivo evaluation. AAPS PharmSciTech. 2017;18(8):2957\u201364.","journal-title":"AAPS PharmSciTech"},{"key":"709_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijpharm.2014.03.054","volume":"467","author":"H Mu\u00f1oz","year":"2014","unstructured":"Mu\u00f1oz H, Castan H, Clares B, Ruiz MA. Obtaining fastdissolving disintegrating tablets with different doses of melatonin. Int J Pharm. 2014;467:84\u20138.","journal-title":"Int J Pharm"},{"issue":"1","key":"709_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1208\/s12249-012-9880-6","volume":"14","author":"X Hu","year":"2013","unstructured":"Hu X, Li Y. Zhang. Preparation and evaluation of orally disintegrating tablets containing taste-masked microcapsules of berberine hydrochloride. AAPS PharmSciTech. 2013;14(1):29\u201337.","journal-title":"AAPS PharmSciTech"},{"key":"709_CR5","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1211\/0022357023691","volume":"56","author":"VB Patravale","year":"2004","unstructured":"Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56:827\u201340.","journal-title":"J Pharm Pharmacol"},{"issue":"2","key":"709_CR6","doi-asserted-by":"publisher","first-page":"161","DOI":"10.4314\/tjpr.v8i2.44525","volume":"8","author":"JJ Hirani","year":"2009","unstructured":"Hirani JJ, Rathod DA, Vadalia KR. Orally disintegrating tablets: a review. Trop J Pharm Res. 2009;8(2):161\u201372.","journal-title":"Trop J Pharm Res"},{"issue":"10","key":"709_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.3109\/03639045.2016.1160102","volume":"42","author":"A Alayoubi","year":"2016","unstructured":"Alayoubi A, Daihom B, Adhikari H. Development of a taste-masked oral suspension of clindamycin HCl using ion exchange resin Amberlite IRP 69 for use in pediatrics. Drug Dev Ind Pharm. 2016;42(10):1579\u201389.","journal-title":"Drug Dev Ind Pharm"},{"key":"709_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ejps.2015.04.006","volume":"75","author":"B Witold","year":"2015","unstructured":"Witold B, Ewelina M, Renata J. Orodispersible films and tablets with prednisolone microparticles. Eur J Pharm Sci. 2015;75:81\u201390.","journal-title":"Eur J Pharm Sci"},{"issue":"11","key":"709_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/03639040701377888","volume":"33","author":"SK Battu","year":"2007","unstructured":"Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegratingfenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007;33(11):1225\u201332.","journal-title":"Drug Dev Ind Pharm"},{"key":"709_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.ejps.2015.02.015","volume":"75","author":"M Slavkova","year":"2015","unstructured":"Slavkova M, Breitkreutz J. Orodispersible drug formulations for children and elderly. Eur J Pharm Sci. 2015;75:2\u20139.","journal-title":"Eur J Pharm Sci"},{"key":"709_CR11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ejpb.2017.10.018","volume":"122","author":"F Gustavo","year":"2018","unstructured":"Gustavo F, Peter K, J\u00f6rg B. Orodispersible tablets containing taste-masked solid lipid pellets with metformin hydrochloride: influence of process parameters on tablet properties. Eur J Pharm Biopharm. 2018;122:137\u201345.","journal-title":"Eur J Pharm Biopharm"},{"key":"709_CR12","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s12247-014-9196-z","volume":"9","author":"BB Emad","year":"2014","unstructured":"Emad BB, Asmaa A, Magdy I. Utility of mannitol and citric acid for enhancing the solubilizing and taste masking properties of \u03b2-cyclodextrin: development of fast-dissolving tablets containing extremely bitter drug. J Pharm Innov. 2014;9:309\u201320.","journal-title":"J Pharm Innov"},{"issue":"11","key":"709_CR13","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/03639040701377888","volume":"33","author":"SK Battu","year":"2007","unstructured":"Battu SK, Repka MA, Majumdar S, Madhusudan RY. Formulation and evaluation of rapidly disintegrating fenoverine tablets: effect of superdisintegrants. Drug Dev Ind Pharm. 2007;33(11):1225\u201332.","journal-title":"Drug Dev Ind Pharm"},{"key":"709_CR14","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/03639040600897150","volume":"33","author":"MR Mutasem","year":"2007","unstructured":"Mutasem MR, Estelle RS, Keith JS. Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics. Drug Dev Ind Pharm. 2007;33:523\u201330.","journal-title":"Drug Dev Ind Pharm"},{"key":"709_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ijpharm.2004.08.019","volume":"292","author":"G Abdelbary","year":"2005","unstructured":"Abdelbary G, Eouani C, Prinderre P, Joachim J, Reynier J, Piccerelle P. Determination of the in vitro disintegration profileof rapidly disintegrating tablets and correlation with oral disintegration. Int J Pharm. 2005;292:29\u201341.","journal-title":"Int J Pharm"},{"key":"709_CR16","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2011.01.027","volume":"153","author":"VF Patel","year":"2011","unstructured":"Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug delivery. J Control Release. 2011;153:106\u201316.","journal-title":"J Control Release"},{"issue":"13","key":"709_CR17","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclo-oxygenase. JAMA Oncol. 2006;296(13):1633\u201344.","journal-title":"JAMA Oncol"},{"issue":"9","key":"709_CR18","doi-asserted-by":"publisher","first-page":"e1001098","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098.","journal-title":"PLoS Med"},{"issue":"4","key":"709_CR19","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.clinthera.2010.04.009","volume":"32","author":"JM Scheiman","year":"2010","unstructured":"Scheiman JM, Hindley CE. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events. Clin Ther. 2010;32(4):667\u201377.","journal-title":"Clin Ther"},{"issue":"1","key":"709_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11239-018-1764-5","volume":"47","author":"G Paul","year":"2019","unstructured":"Paul G, Udaya T, Steven W. A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. J Thromb Thrombolysis. 2019;47(1):16\u201330.","journal-title":"J Thromb Thrombolysis"},{"key":"709_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1080\/03639040500528913","volume":"32","author":"S Iman","year":"2006","unstructured":"Iman S, Nafadi M, Faten F. Formulation of a fast-dissolving ketoprofen tablet using using freeze drying in blister technique. Drug Dev Ind Pharm. 2006;32:437\u201342.","journal-title":"Drug Dev Ind Pharm"},{"issue":"9","key":"709_CR22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1080\/03639045.2017.1318905","volume":"43","author":"A Ebtessam","year":"2017","unstructured":"Ebtessam A, Amira O, Ahmed M, Gamal M. Controlled precipitation for enhanced dissolution rate of flurbiprofen: development of rapidly disintegrating tablets. Drug Dev Ind Pharm. 2017;43(9):1430\u20139.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"709_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejpb.2007.11.011","volume":"69","author":"F Adamo","year":"2008","unstructured":"Adamo F, Valentina B, Gian CC, Celestino R, Carlos AFM. Fast dispersible\/slow releasing ibuprofen tablets. Eur J Pharm Biopharm. 2008;69(1):335\u201341.","journal-title":"Eur J Pharm Biopharm"},{"key":"709_CR24","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.2042-7158.1975.tb09378.x","volume":"27","author":"KA Khan","year":"1975","unstructured":"Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol. 1975;27:48\u20139.","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"709_CR25","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1365-2125.2005.02223.x","volume":"59","author":"Y Zhang","year":"2005","unstructured":"Zhang Y, Zhong D, Si D, Guo Y, Chen X, Zhou H. Lornoxicam pharmacokinetics in relation to cytochrome P 450 2C9 genotype. Br J Clin Pharmacol. 2005;59(1):14\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"709_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejpb.2008.11.011","volume":"72","author":"R Chandrasekhar","year":"2009","unstructured":"Chandrasekhar R, Hassan Z, Alhusban F, Smith AM, Mohammed AR. The role of formulation excipients in the development of lyophilised fast-disintegrating tablets. Eur J Pharm Biopharm. 2009;72:119\u201329.","journal-title":"Eur J Pharm Biopharm"},{"key":"709_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ejpb.2010.03.012","volume":"75","author":"F AlHusban","year":"2010","unstructured":"AlHusban F, Perrie Y, Mohammed AR. Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents. Eur J Pharm Biopharm. 2010;75:254\u201362.","journal-title":"Eur J Pharm Biopharm"},{"key":"709_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.ejpb.2009.04.005","volume":"73","author":"RA Shoukri","year":"2009","unstructured":"Shoukri RA, Ahmed IS, Shamma RN. In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets. Eur J Pharm Biopharm. 2009;73:162\u201371.","journal-title":"Eur J Pharm Biopharm"},{"key":"709_CR29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.ijpharm.2005.09.009","volume":"306","author":"T Mizumoto","year":"2005","unstructured":"Mizumoto T, Masuda Y, Yamamoto T, Yonemochi E, Terada K. Formulation design of a novel fast-disintegrating tablet. Int J Pharm. 2005;306:83\u201390.","journal-title":"Int J Pharm"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00709-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13346-020-00709-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-020-00709-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T13:24:12Z","timestamp":1613741052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13346-020-00709-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,18]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s13346-020-00709-4","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,18]]},"assertion":[{"value":"18 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (Faculty of Pharmacy, Cairo University, Egypt; ethical code PI:1721) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}